A literature review of the main factors influencing the e-commerce and last-mile delivery projects during COVID-19 pandemic

Humanity has faced many pandemics throughout its history with COVID-19 pandemic being the most recent. Each pandemic requires the implementation of a series of restrictions and measures to reform local societies or even society on a global scale. Scientific and technological innovations have ensured the survival of mankind and consequently the establishment of new habits and trends. One of these reforms concerns the transport of goods and in particular urban logistics and last-mile delivery. Despite the increasing use of e-commerce, the average amount of money spent per month and per buyer has decreased;in times of uncertainty, people prefer to postpone big purchases and focus more on everyday products. These purchases have generated an increase in demand for the transport of goods and put significant pressure on the supply chain. For this reason, actions have been developed to improve logistics, in particular last-mile delivery, with the introduction of environmentally friendly and small vehicles, among others. In order to be able to trace the evolution of the combination of the COVID-19 pandemic and logistics spatially and temporally, the manuscript focused as a first step on the analysis of the literature entered in the main databases dedicated to scientific publications, returning some 2,227 indexed articles from 2000 to 2021. The search was conducted using keywords and iterations between them. The results emphasised the need to adapt business activities to the changing situation by anticipating people's needs, creating e-commerce sites capable of accompanying customers in this delicate phase. The results obtained were analysed from a statistical point of view, laying the foundations for future investigative steps in the field of last-mile logistics and the proper planning of loading and unloading spaces for goods in urban areas. © 2023 The Authors. Published by ELSEVIER B.V.

Allowing privacy-preserving fog computing with digital identity assurance in remote clinical services

Nowadays, there is an increasing demand for cloud-based remote clinical services, both for diagnosis and monitoring. The COVID-19 pandemic has dramatically amplified this need. E-government programs should quickly go towards the expansion of this type of services, also to avoid that people (especially elderly) renounce treatment or adequate healthcare. However, to be effective, latency between IoT medical devices and the cloud should be reduced as much as possible. For this reason, fog computing appears the best approach, as part of the elaboration is moved closer to the user. However, some privacy threats arise. Indeed, these services can be delivered only based on secure digital identity and authentication systems, but the intermediate fog layer should learn nothing about the identity of users and the link among different service requests. In this paper, we propose a concrete solution to the above issue by leveraging eIDAS-compliant digital identity and by including a cryptographic protocol to provide anonymity and unlinkability of user's access to fog servers. Copyright © 2023 Inderscience Enterprises Ltd.

Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.

INTRODUCTION: Ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in patients hospitalized in intensive care units (ICUs) is an important and challenging complication, including in patients with coronavirus disease 2019 (COVID-19). Considering the poor lung penetration of most antibiotics, including intravenous colistin due to the poor pharmacokinetics/pharmacodynamics at the infection site, the choice of the best antibiotic regimen is still being debated. METHODS: This single-centre, observational study was conducted from March 2020 to August 2022, and included all patients hospitalized consecutively with VAP and concomitant bloodstream infection due to CRAB in the COVID-ICU. The main goal of the study was to evaluate risk factors associated with survival or death at 30 days from VAP onset. A propensity score for receiving therapy was added to the model. RESULTS: During the study period, 73 patients who developed VAP and concomitant positive blood cultures caused by CRAB were enrolled in the COVID-ICU. Of these patients, 67 (91.7%) developed septic shock, 42 (57.5%) had died at 14 days and 59 (80.8%) had died at 30 days. Overall, 54 (74%) patients were treated with a colistin-containing regimen and 19 (26%) were treated with a cefiderocol-containing regimen. Cox regression analysis showed that chronic obstructive pulmonary disease and age were independently associated with 30-day mortality. Conversely, cefiderocol-containing regimens and cefiderocol + fosfomycin in combination were independently associated with 30-day survival, as confirmed by propensity score analysis. CONCLUSIONS: This real-life study in patients with bacteraemic VAP caused by CRAB provides useful suggestions for clinicians, showing a possible benefit of cefiderocol and its association with fosfomycin.

European destination regions and social exclusion challenges

This paper presents a typology of European regions according to the type, mix and magnitude of human mobilities attracted over the 2008–2018 period, tourists being one of them, but extending to the related movement of different cohorts of migrants. Regional clusters are then assessed in terms of their social performance in domains such as health, material conditions, housing, and labour. Significant associations between regional types and social trends are interpreted in the light of potential factors affecting these outcomes. Results point to the uneven repercussions of housing unaffordability in the fastest growing destination regions, on the polarisation of living conditions in the European ‘star destinations' and on the challenge of precarious labour, especially for migrant workers, in established mature destinations. In a stage of reignition of tourism activity after the COVID-19 crisis, these insights are meant to contribute to the recovery debate, informing about key social issues and vulnerabilities which, in specific regional contexts, could have been amplified by the current crisis. Copyright © 2022 Inderscience Enterprises Ltd.

The Next Generation of eHealth: A Multidisciplinary Survey

Over the past two years, the spread of COVID-19 has spurred the use of information and communication technologies (ICT) in aid of healthcare. The need to guarantee continuity to care has promoted research and industry activities aimed at developing solutions for the digitalization of the procedures to be performed to provide health services, even in emergency scenarios. Digital collection, transmission, and processing of health data represent the starting point for fulfilling this innovation process but also bring heterogeneous challenges. These motivations led to the elaboration of this work, which analyzes innovative and technological tools for the development of digital health (eHealth) through the collection of multisectoral literature, produced thanks to the cooperation of varied research groups, thus providing a multidisciplinary survey. Since digital health is expected to be one of the leading applications of the sixth-generation (6G) wireless cellular networks, this paper covers the related telecommunications aspects. Furthermore, the exploitation of artificial intelligence paradigms to elaborate massive amounts of biological data is examined. Given the extreme sensitivity of health data, this paper also investigates security and privacy issues. In particular, the main techniques and approaches to guarantee security properties (i.e., anonymity, responsibility, authentication, confidentiality, integrity, non-repudiation, and revocability) are studied. Applications involving innovative electromagnetic systems for healthcare and assisted living services are described to provide an example of an eHealth scenario leveraging ICT. Finally, the telemedicine-related regulations of the European Commission are analyzed, with particular reference to the General Data Protection Regulation (GDPR).

Beyond Brugada Syndrome: A Common Ecg Pattern in an Uncommon Clinical Scenario

Propofol infusion syndrome (PRIS) is a rare but potentially lethal side effect of propofol. In most cases it shows various combinations of signs such as unexplained metabolic acidosis, rhabdomyolysis, hepatomegaly, renal failure, hypertriglyceridemia, malignant arrhythmia and rapidly progressive cardiac failure. The development of coved ST elevation in the right precordial leads of the electrocardiogram (ECG), similar to that seen in the type I Brugada syndrome may be the first sign of cardiac instability. There is no specific treatment for PRIS. Successful management consists of an early recognition of its signs followed by a prompt propofol infusion termination. We present the case of a 35-year-old male affected by mild hypertension. He was found by his wife during a transitory loss of consciousness episode. He had resulted positive to Sars Cov 2 infection a day before and was symptomatic for fever and myalgia. An ambulance was immediately called and the patient was transferred to the emergency department for a suspected out-of-hospital-cardiac arrest. The initial one-lead ECG performed by the emergency physician was unremarkable. On arrival he was in a coma state but with stable hemodynamics. ECG showed only an asymmetric T wave inversion in V4-V6 leads. The cardiac echocardiogram did not show any major alterations. In the meantime, due to worsening of respiratory function, orotracheal intubation was performed and the patient was sedated with propofol, midazolam and fentanyl. Subsequently, an episode of atrial fibrillation was documented. Amiodarone infusion was started and the patient reverted to sinus rhythm after a few hours. The following day two episodes of Torsade de Pointes during prolonged QTc (660 ms) occurred. These arrhythmias were treated successfully with magnesium sulfate infusion. Blood analysis showed severe hypokalemia that was immediately corrected. After the hemodynamic stabilization the ECG showed a pattern highly resembling the Brugada pattern type 1 in the right precordial leads. Moreover CPK, myoglobin, high sensitivity troponin I levels started to rise, along with creatinine, triglycerides and markers of hepatic injury. Propofol had been administered continuously for eight days, so PRIS was suspected as the primum movens of this clinical scenario. Propofol infusion was immediately interrupted. Thereafter, the patient gradually improved and was extubated. As soon as the patient's hemodynamic conditions allowed it, a coronary CT and a cardiac MRI were performed, but were unremarkable. To further evaluate the case, a flecainide challenge test was performed, but no significant ECG change was induced. Nonetheless, given both the history of ventricular arrhythmia, the young age of the patient and the unexplained transitory loss of consciousness a subcutaneous defibrillator was implanted as a form of secondary prevention..

Preexisting mild cognitive impairment as a risk factor for COVID-19 infection: A scoping review and case reports

Introduction: SARS-Co-V2 neuroinvasive ability might be the basis for the onset of delirium and neuropsychiatric outcomes. Objective(s): We hypothesized that some infected patients with preexisting cognitive dysfunction may present delirium as unique manifestation of COVID-19 infection or as a prodrome of a new episode consistent with the psychiatric history. Method(s): We conducted a PubMed literature search to verify whether cognitive impairment might predispose to COVID-19. We included three patients with mild cognitive impairment and delirium at admission for SARS-Co-V2 suspected infection. Delirium was diagnosed according to DSM-5 criteria, Cognitive Assessment Method and Coma Glasgow Scale. Result(s): Literature analysis evidenced patients presenting delirium or delirium-like symptoms as clinical manifestation of COVID-19, plus a cognitive impairment, from mild to severe, which preexisted or was evidenced during the acute phase or after the infection. Most studies described delirium in patients with a past neurological/ psychiatric history. Contrasting data emerged on the potential link between COVID-19 and delirium in patients with cognitive impairment and without a past neuropsychiatric history. Our patients had no history of other medical complications. Our first patient had no psychiatric history, the second reported only a depressive episode, and the third had story of bipolar disorder. Delirium resolved completely after 2 days in the first patient. The other patients required 4 and 14 days to resolve: delirium appeared as the prodrome of a new psychiatric episode in line with their past history. Conclusion(s): Clinicians should acknowledge the possibility that COVID-19 infection may appear as delirium and acute psychiatric sequelae as unique manifestation.

Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC

Background: RET fusions are found in 1-2% of patients (pts) with advanced non-small cell lung cancer (aNSCLC). Targeted therapy with RET inhibitors (RETi) significantly improved prognosis. Molecular mechanisms of resistance are still incompletely characterized. Methods: This multicentric retrospective study included 24 centres. Eligible pts had a RET+ aNSCLC, were treated with a RETi and had at least one molecular profile by next-generation sequencing (NGS), performed before and/or after RETi, on tissue and/or plasma samples. Primary resistance under RETi was defined as disease progression (PD) within 6 months of therapy. Results: 95 patients were included with 112 biopsies: 93 at baseline, 19 at PD. 17 patients had paired NGS (baseline and PD). Median age was 65 years (range 56-72);62% were female, 54% were never smokers, 17% had brain metastasis (BM) at diagnosis. 55 patients received pralsetinib, 36 selpercatinib, 4 other RETi. Overall, median PFS under RETi was 17.1 months (95%CI 12.6-28). Primary resistance to RETi occurred in 22 (23%) patients. Primary resistant versus durable responders to RETi had non-adenocarcinoma histology in 9% vs 46% (p=0.61), smoking history in 57% vs 40% (p=0.21), BM in 5% vs 21% (p=0.1), TP53 mutations in 37% vs 22% (p=0.23). KRAS G12V mutation and SMARCA4 alterations were found only in poor responders (4.5% vs 0%, p=0.2;and 25% vs 0%, p=0.04, respectively). Among biopsies at PD (N=19, 13 liquid and 6 tissue biopsies), 7/13 (54%) liquid biopsies failed due to insufficient ctDNA. In 12 evaluable pts, 3 (25%) acquired secondary RET mutations (2 G810S and 1 S904F), 3 (25%) had novel RET rearrangements (2 in intron 11, 1 RET-DOCK1, 1 RET-CSGALNACT2) and 3 (25%) pts had off-target alterations (2 MET and 1 MYC amplification). Three pts (25%) developed novel TP53 mutations, while 3 (25%) had no novel identifiable alterations at PD. Conclusions: SMARCA4 and KRAS co-mutations may have a role in primary resistance to RETi. Secondary RET mutations, novel RET rearrangements and MET/MYC amplifications were identified after treatment with RETi. More than half of pts had insufficient ctDNA at PD, making tissue biopsy essential to identify resistance mechanisms. Legal entity responsible for the study: Institut Gustave Roussy. Funding: Has not received any funding. Disclosure: V. Fallet: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Takeda, Roche, Pfizer, Sanofi, Sandoz, Jansen;Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Takeda, Pfizer, MSD;Financial Interests, Personal, Expert Testimony: GSK, Boehringer. C. Audigier-Valette: Financial Interests, Personal, Advisory Role: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Ipsen, Eli Lilly, Novartis, Pfizer, and Roche. A. Russo: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, MSD, Novartis;Financial Interests, Personal, Writing Engagements: AstraZeneca, Novartis. A. Calles Blanco: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Pfizer, Roche, Lilly, Merck Sharp & Dohme, Novartis, Bristol-Myers Squibb, Takeda, Sanofi;Financial Interests, Personal, Other, Speaker honoraria: Bayer;Financial Interests, Institutional, Research Grant, Drug-only for Investigator-initiated trial: Merck Sharp & Dohme. P. Iranzo Gomez: Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb Recipient, F. Hoffmann, La Roche AG, Merck Sharp & Dohme, Boehringer Ingelheim, MSD Oncology, Rovi, Yowa Kirin, Grunenthal Pharma S.A., Pfizer. M. Tagliamento: Financial Interests, Personal, Other, medical writer: Novartis, Amgen;Financial Interests, Personal, Invited Speaker, travel/accommodation: Roche, Bristol-Myers Squibb, AstraZeneca, Takeda. L. Mezquita: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, Roche;Financial Interests, Personal, Invited Speaker: Roche, BMS, AstraZeneca, Takeda;Financial Interests, Personal, Research Grant, SEOM Beca Retorno 2019: BI;Financial Interests, Personal, Research Grant, ESMO TR Research Fellowship 2019: BMS;Financial Interests, Institutional, Research Grant, COVID research Grant: Amgen;Financial Interests, Institutional, Invited Speaker: Inivata, Stilla. C. Lindsay: Financial Interests, Institutional, Principal Investigator: Roche, Amgen, BI;Financial Interests, Personal, Advisory Role: CBPartners, Amgen. S. Ponce: Financial Interests, Institutional, Principal Investigator: Merck Sharp and Dohme, F. Hoffmann-La Roche, Foundation Medicine, PharmaMar. Personal fees: Merck Sharp and Dohme, Bristol-Myers Squibb, F. Hoffmann-La Roche, Foundation Medicine, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Celgene.;Financial Interests, Personal, Advisory Board: Merck Sharp and Dohme, Bristol-Myers Squibb, F. Hoffmann-La Roche, Foundation Medicine, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Celgene.;Non-Financial Interests, Personal, Other: Merck Sharp and Dohme, Bristol-Myers Squibb, F. Hoffmann-La Roche. M. Aldea: Financial Interests, Personal, Invited Speaker, travel/accommodation: Sandoz. All other authors have declared no conflicts of interest.

COVID-19 lockdown negatively impacted on adherence to denosumab therapy: incidence of non-traumatic fractures and role of telemedicine.

PURPOSE: Coronavirus disease (COVID-19) lockdowns have impacted on management of osteoporosis and the use of telemedicine is increasingly widespread albeit supported by little evidence so far. The aim of the study is to assess adherence to denosumab and incidence of non-traumatic fractures during the lockdown compared to the pre-COVID-19 year and to explore the effectiveness of telemedicine in the management of osteoporotic patients. METHODS: Retrospective, longitudinal, single-center study on patients receiving subcutaneous denosumab therapy every 6 months. Each patient was scheduled to undergo 2 visits: one during the pre-COVID-19 period (March 2019-March 2020) and another visit during the lockdown period (March 2020-March 2021). Data on new fractures, adherence, risk factors for osteoporosis and the modality of visit (telemedicine or face-to-face) were collected. RESULTS: The prevalence of non-adherent patients was higher during the lockdown (35 of 269 patients, 13.0%) than the pre-COVID-19 period (9 of 276 patients, 3.3%) (p < 0.0001). During the lockdown, the number of new non-traumatic fractures was higher than the pre-COVID-19 year (p < 0.0001): 10 patients out of 269 (3.7%) experienced a fragility fracture and 2 patients (0.7%) a probable rebound fracture during the lockdown period, whereas no patient had fragility/rebound fractures during the pre-COVID-19 period. No difference was found in the prevalence of non-adherence and new non-traumatic fractures comparing patients evaluated with tele-medicine to those evaluated with face-to-face visit. CONCLUSION: Non-adherent patients and new non-traumatic fractures (including rebound fractures) were more prevalent during the lockdown in comparison to the pre-COVID-19 period, regardless of the modality of medical evaluation.

Implementing Systematic Screening Driven by Quality Improvement Education (QIE) for Atrial Fibrillation during the Covid-19 Pandemic: Insight from Primary Care Setting in the United States

Background: Asymptomatic patients with atrial fibrillation (AF) pose challenges to diagnosis. Early diagnosis can reduce morbidity and mortality. Systematic screening in primary care may result in early intervention. Objectives: We sought to examine the implementation outcomes of a systematic, team-based quality improvement education (QIE) intervention for AF screening in primary care during the COVID-19 pandemic. Methods: QIE intervention was implemented in academic-based (n=4) and community-based (n=2) practices to address COVID-19 challenges. Surveys administered by site identified existing approaches and provider teams developed screening protocol based on targeted education, deploying a mobile ECG device (Kardiamobile™). Patient charts were reviewed (Dec 2020-May 2021) to determine eligibility, i.e., patients aged 65-74 (with prior stroke/TIA or two other risk factors) or aged ≥75 (with one other risk factor) without prior AF. Patient EHR data were examined for demographic/clinical data and screening outcome. Provider interviews (n=12) and validation from representative patients (n=2) accounted for sustainability of outcomes. Results: A total of 1,221 patients were evaluated for AF risk, with 408 eligible for screening. Of these, 277 (68%) were female and CHA2DS2-VASc varied-score=3 (45%);score=4 (24%);score=5+ (31%). Patients (n=7;2%) who screened positive for AF were referred or started on anticoagulation, like other primary care studies. Figure 1 shows how systematic screening was re-imagined and implemented Satisfaction and engagement increased among providers and patients-attributed, in part, to benefits of team-based planning and targeted education. Conclusion: An AF screening program was adapted to improve patient care despite COVID-19 related challenges. A QIE toolkit was launched to assist primary care practices with implementing streamlined, sustainable, and patient-engaging strategies to reduce stroke.

COVID-19 and SARS-CoV-2. We learn that there's still so much more to learn

Background: Current COVID-19 pandemic exposes health staff to a new and potentially fatal disease Case history: Male, 37 yo, entered ER referring worsening asthenia, feeling non-specifically unwell for 7 days, recent history of SARSCoV- 2 infection with interstitial pneumonia requiring hospitalization two weeks prior admission. Blood tests showed severe anemia (Hb 4gr/dl), mild hyperbilirubinemia, markedly raised LDH, positive direct/ indirect Coombs' reaction. Autoimmune haemolytic anemia was suspected because of symptomatic anaemia, evidence of ongoing haemolysis on blood tests, history of a viral infection. Chest XRay and CT pulmonary angiogram were negative for features suggestive of Covid-19 but highlighted lower right lobar pneumonia. Nasopharyngeal molecular swab was negative, while antibody test showed high titer G Immunoglobulin, confirming recent infection. He was initially treated with high doses steroids (1 gr/Kg bw) as well as antibiotics for pneumonia;but, due to lack of efficacy, on the fourth day we started ev immunoglobulins, obtaining gradual improvement in Hb towards baseline and tests normalization. Discussion: SARS-CoV2 infection frequently meets complications;although the pathophysiology underlying COVID-19 remains poorly understood, evidence argues for hyperinflammatory syndrome and/or various autoimmune disorders, which may appear after pneumonia recovery, highlighting need of medium and longterm follow up, to identify possible presentations of COVID-19 complications.

The impact of digital technologies on the achievement of the Sustainable Development Goals: evidence from the agri-food sector

The business world has suffered a great shock: the COVID 19 pandemic has changed the competitive model of companies. Nowadays, companies have to deal with the pressures of stakeholders who, also due to the pandemic, are increasingly attentive to the firm’s impacts on the environment and health. Thus, companies voluntarily undertake to provide information on their strategies in a way that better addresses concerns about digitization and sustainability. This paper aims to analyze the impact of digital technologies on the achievement of the Sustainable Development Goals (SDGs) of the 2030 Agenda. To this end, a cross-case analysis of companies active in the Italian agri-food sector was carried out. In more detail, a content analysis methodology has been used to analyze the published sustainability reports, focusing on the digital technologies used and identifying the SDGs already reached and/or reachable by the company. Digital technologies have been classified, and each technology has been associated with appropriate SDGs through a deductive approach. Findings demonstrate a clear link between digitalization the SDGs achievement. The disruption provoked by COVID-19 caused the introduction of a ‘new normal’ for the digital technologies that must be weighed considering social and environmental repercussions in the agri-food sector. © 2022 Informa UK Limited, trading as Taylor & Francis Group.

Boosters and time since last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment

BACKGROUND: the levels of anti-SARS-CoV-2 antibodies after the second vaccine dose decline in the following months;an additional vaccine dose (booster) is able to swiftly restore the immune system, significantly reducing the risk of severe disease. In the winter of 2021, a new, particularly infectious variant made the need to increase booster coverage in the population even more urgent. OBJECTIVES: to present, using real data, an evaluation of the effectiveness of the booster dose in reducing severe disease caused by SARS-CoV-2 infection in terms of COVID-19 hospitalization and intensive care admission, and all-cause mortality. DESIGN: descriptive study of vaccination uptake;associative study of the factors linked with uptake of vaccination and COVID-19 symptoms;associative study of vaccine effectiveness against hospital admission and mortality. SETTING AND PARTICIPANTS: population residing in the Milan and Lodi provinces (Lombardy Region, Northern Italy), eligible for anti-SARS-COV-2 vaccination, with subjects aged >= 19 years alive as at 01.10.2021, not residing in nursing homes, followed-up until 31.12.2021. MAIN OUTCOME MEASURES: COVID-19 symptoms, hospitalization, intensive care hospitalization, and all-cause mortality in the period 01.10.2021-31.12.2021. RESULTS: the cohort included 2,936,193 patients as of 01.10.2021;at the end of the observation period (31.12.2021), 378,616 (12.9%) were unvaccinated, 60,102 (2.0%) had received only 1 dose and had not had the disease, 68,777 (2.3%) had received only 1 dose and had had the disease, 412,227 (14.0%) were fully vaccinated with 2 doses less than 4 months earlier, 198,459 (6.8%) had received 2 doses [4,5) months earlier, 439,363 (15.0%) had received 2 doses [5,6) months earlier, 87,984 (3.0%) had received 2 doses [6,7) months earlier, 74,152 (2.5%) had received 2 doses more than 7 months earlier, 62,614 (2.1%) had received 2 doses and had had the disease, and, finally, 1,153,899 (39.3%) had received a booster shot. In the study period (01.10.2021-31.12.2021), characterized by a very high prevalence of the omicron variant, 121,620 cases (positive antigen/molecular test), 3,661 hospitalizations for COVID-19, 162 intensive care admissions for COVID-19, and 7,508 deaths from all causes were identified. Compared to unvaccinated subjects, subjects who received a booster had half the risk of being symptomatic, and had half the risk of experiencing fatigue, muscle aches, and dyspnoea. In comparison with boosted subjects, unvaccinated subjects had a 10-fold risk of hospitalization, a 9-fold risk of intensive care, and a 3-fold risk of dying. CONCLUSIONS: this work highlights the effectiveness of vaccination in reducing serious adverse events in boosted subjects and the need to implement specific policies of engagement to bring subjects who received their second dose earliest to get a booster.